Methotrexate (MTX) and methylprednisolone (MP) treatment of peripheral blood mononuclear cells (PBMCs) from patients with early RA promotes expansion of IL-10+Th17 cells (56). The gene discussed is IL10; the disease is rheumatoid arthritis.